Premium
Pharmacokinetics and analgesic effect of ropivacaine following ilioinguinal/iliohypogastric nerve block in children
Author(s) -
Dalens Bernard,
Ecoffey Claude,
Joly Agnes,
Giaufré Elisabeth,
Gustafsson Urban,
Huledal Gunilla,
Larsson Lars E.
Publication year - 2001
Publication title -
pediatric anesthesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.704
H-Index - 82
eISSN - 1460-9592
pISSN - 1155-5645
DOI - 10.1046/j.1460-9592.2001.00691.x
Subject(s) - ropivacaine , medicine , analgesic , anesthesia , pharmacokinetics , nerve block , neuropathic pain , surgery , pharmacology
Background: The aim was to investigate the efficacy, tolerance and pharmacokinetics of ropivavcaine when administered for ilioinguinal/iliohypogastric block in children. Methods: We examined the pharmacokinetics and analgesic efficacy after ilioinguinal/iliohypogastric nerve block with 3 mg·kg −1 ropivacaine 5 mg·ml −1 in 22 children, aged 1–12 years, who were scheduled for inguinal surgery. Sixteen of 22 patients had a postoperative pain score < 4 (Objective Pain Scale). Nine children were given supplementary analgesics during the first six postoperative hours. Results: The peak plasma concentration of total ropivacaine was 1.50 ± 0.93 mg·l −1 (mean ± SD) (range 0.64–4.77 mg·l −1 ) 15–64 min after the injection. The peak plasma concentration of free ropivacaine was 0.05 ± 0.03 mg·l −1 (0.02–0.14 mg·l −1 ), which is well below the threshold for toxicity in adults. The terminal half‐life was 2.0 ± 0.7 h. No safety concerns or symptoms suggestive of systemic toxicity were observed. Conclusions: A dose of 3 mg·kg −1 of ropivacaine given as a single ilioinguinal/iliohypogastric nerve block in 1–12‐year‐old children provides satisfactory postoperative pain relief, and is well tolerated.